Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for 22407B108 since 12/18/2024, newest first.
| Filer | % of Class | Filed | |
|---|---|---|---|
|
Orin Hirschman
13G/A
Amendment 3
|
3.3% |
7/27/2026
Event 6/30/2026
|
|
| Orin Hirschman | 3.3% | ||
| AIGH Capital Management LLC | 2.7% | ||
|
Dr. Reddy's Laboratories, Inc.
13G
|
9.7% |
3/12/2026
Event 1/30/2026
|
|
| Dr. Reddy's Laboratories, Inc. | 9.7% | ||
| Dr. Reddy's Laboratories SA | 9.7% | ||
| Dr. Reddy's Laboratories Limited | 9.7% | ||
| Vanguard Group Inc 13G/A Amendment 2 | 4.3% |
1/30/2026
Event 12/31/2025
|
|
|
Orin Hirschman
13G/A
Amendment 3
|
5.3% |
1/28/2026
Event 12/31/2025
|
|
| Orin Hirschman | 5.3% | ||
| AIGH Capital Management LLC | 4.7% | ||
|
DME Capital Management, LP
13G/A
Amendment 2
|
9.9% |
2/14/2025
Event 12/31/2024
|
|
| DME Capital Management, LP | 7.6% | ||
| DME Advisors, LP | 2.3% | ||
| DME Advisors GP, L.L.C. | 9.9% | ||
| Einhorn David | 9.9% | ||
|
Orin Hirschman
13G/A
Amendment 2
|
8.0% |
2/10/2025
Event 12/31/2024
|
|
| Orin Hirschman | 8.0% | ||
| AIGH Capital Management LLC | 7.2% |
| Period | Filings | Shares, Excl. Options | Value, Excl. Options |
|---|---|---|---|
| 2026 Q3 | 2 | 26.2 k | $131 k |
| 2026 Q2 | 55 | 7.78 M | $45.5 M |
| 2026 Q1 | 58 | 8.13 M | $32.0 M |
| 2025 Q4 | 58 | 7.94 M | $46.0 M |
| 2025 Q3 | 37 | 4.76 M | $27.1 M |
| 2025 Q2 | 35 | 4.50 M | $25.9 M |
| 2025 Q1 | 27 | 4.66 M | $30.2 M |
| 2024 Q4 | 27 | 4.44 M | $25.5 M |
| 2024 Q3 | 21 | 3.32 M | $21.4 M |
| 2024 Q2 | 22 | 3.27 M | $19.8 M |
| 2024 Q1 | 23 | 3.34 M | $33.1 M |
| 2023 Q4 | 24 | 2.82 M | $20.7 M |
| 2023 Q3 | 16 | 1.42 M | $5.45 M |
| 2023 Q2 | 15 | 1.35 M | $5.50 M |
| 2023 Q1 | 8 | 1.10 M | $4.37 M |
| 2022 Q4 | 5 | 1.09 M | $5.16 M |